Be a part of Ceapro
Ceapro is committed to generating sustained shareholder value. We are an innovative, revenue generating, and profitable company providing quality products to global multi-billion dollar health care industries.
Ceapro is revenue driven, science focused junior biotech listed on the TSX-V under the trading symbol CZO.
Ceapro reports its quarterly earnings reports and management discussion and analysis for the periods ended March 31, June 30, and September 30 within 60 days of the end of the reporting period. Ceapro’s annual audited financial statements and accompanying management discussion and analysis are issued within 120 days of the December 31 year end.
For Marketwire news items and other Ceapro news, please visit News.